Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 241 to 245 of 245 entries
Sorted by: Best Match Show Resources per page
Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury.

Experimental neurology

Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, Abdelrahman AA, Cheng PN, Narayanan SP, Caldwell RW, Caldwell RB.
PMID: 34780773
Exp Neurol. 2021 Nov 12;348:113923. doi: 10.1016/j.expneurol.2021.113923. Epub 2021 Nov 12.

Arginase 1 (A1) is the enzyme that hydrolyzes the amino acid, L-arginine, to ornithine and urea. We have previously shown that A1 deletion worsens retinal ischemic injury, suggesting a protective role of A1. In this translational study, we aimed...

Cite
Fouda AY, Eldahshan W, Xu Z, et al. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2021;348:113923doi: 10.1016/j.expneurol.2021.113923.
Fouda, A. Y., Eldahshan, W., Xu, Z., Lemtalsi, T., Shosha, E., Zaidi, S. A., Abdelrahman, A. A., Cheng, P. N., Narayanan, S. P., Caldwell, R. W., & Caldwell, R. B. (2021). Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Experimental neurology, 348113923. https://doi.org/10.1016/j.expneurol.2021.113923
Fouda, Abdelrahman Y, et al. "Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury." Experimental neurology vol. 348 (2021): 113923. doi: https://doi.org/10.1016/j.expneurol.2021.113923
Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, Abdelrahman AA, Cheng PN, Narayanan SP, Caldwell RW, Caldwell RB. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2021 Nov 12;348:113923. doi: 10.1016/j.expneurol.2021.113923. Epub 2021 Nov 12. PMID: 34780773.
Copy Download .nbib Format: NLM
Mild hypobaric hypoxia influences splenic proliferation during the later phase of stress erythropoiesis.

Experimental biology and medicine (Maywood, N.J.)

Zhang L, Patel S, Soulakova JN, Caldwell CC, St Pierre Schneider B.
PMID: 34904451
Exp Biol Med (Maywood). 2021 Dec 14;15353702211060775. doi: 10.1177/15353702211060775. Epub 2021 Dec 14.

Tissue trauma and hemorrhagic shock are common battlefield injuries that can induce hypoxia, inflammation, and/or anemia. Inflammation and hypoxia can initiate adaptive mechanisms, such as stress erythropoiesis in the spleen, to produce red blood cells and restore the oxygen...

Cite
Zhang L, Patel S, Soulakova JN, et al. Mild hypobaric hypoxia influences splenic proliferation during the later phase of stress erythropoiesis. Exp Biol Med (Maywood). 2021;15353702211060775doi: 10.1177/15353702211060775.
Zhang, L., Patel, S., Soulakova, J. N., Caldwell, C. C., & St Pierre Schneider, B. (2021). Mild hypobaric hypoxia influences splenic proliferation during the later phase of stress erythropoiesis. Experimental biology and medicine (Maywood, N.J.), 15353702211060775. https://doi.org/10.1177/15353702211060775
Zhang, Liyuan, et al. "Mild hypobaric hypoxia influences splenic proliferation during the later phase of stress erythropoiesis." Experimental biology and medicine (Maywood, N.J.) vol. (2021): 15353702211060775. doi: https://doi.org/10.1177/15353702211060775
Zhang L, Patel S, Soulakova JN, Caldwell CC, St Pierre Schneider B. Mild hypobaric hypoxia influences splenic proliferation during the later phase of stress erythropoiesis. Exp Biol Med (Maywood). 2021 Dec 14;15353702211060775. doi: 10.1177/15353702211060775. Epub 2021 Dec 14. PMID: 34904451.
Copy Download .nbib Format: NLM
Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow.

Nature biomedical engineering

Xie C, Zhuang XX, Niu Z, Ai R, Lautrup S, Zheng S, Jiang Y, Han R, Gupta TS, Cao S, Lagartos-Donate MJ, Cai CZ, Xie LM, Caponio D, Wang WW, Schmauck-Medina T, Zhang J, Wang HL, Lou G, Xiao X, Zheng W, Palikaras K, Yang G, Caldwell KA, Caldwell GA, Shen HM, Nilsen H, Lu JH, Fang EF.
PMID: 34992270
Nat Biomed Eng. 2022 Jan 06; doi: 10.1038/s41551-021-00819-5. Epub 2022 Jan 06.

A reduced removal of dysfunctional mitochondria is common to aging and age-related neurodegenerative pathologies such as Alzheimer's disease (AD). Strategies for treating such impaired mitophagy would benefit from the identification of mitophagy modulators. Here we report the combined use...

Cite
Xie C, Zhuang XX, Niu Z, et al. Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng. 2022;doi: 10.1038/s41551-021-00819-5.
Xie, C., Zhuang, X. X., Niu, Z., Ai, R., Lautrup, S., Zheng, S., Jiang, Y., Han, R., Gupta, T. S., Cao, S., Lagartos-Donate, M. J., Cai, C. Z., Xie, L. M., Caponio, D., Wang, W. W., Schmauck-Medina, T., Zhang, J., Wang, H. L., Lou, G., Xiao, X., Zheng, W., Palikaras, K., Yang, G., Caldwell, K. A., Caldwell, G. A., Shen, H. M., Nilsen, H., Lu, J. H., & Fang, E. F. (2022). Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nature biomedical engineering, . https://doi.org/10.1038/s41551-021-00819-5
Xie, Chenglong, et al. "Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow." Nature biomedical engineering vol. (2022). doi: https://doi.org/10.1038/s41551-021-00819-5
Xie C, Zhuang XX, Niu Z, Ai R, Lautrup S, Zheng S, Jiang Y, Han R, Gupta TS, Cao S, Lagartos-Donate MJ, Cai CZ, Xie LM, Caponio D, Wang WW, Schmauck-Medina T, Zhang J, Wang HL, Lou G, Xiao X, Zheng W, Palikaras K, Yang G, Caldwell KA, Caldwell GA, Shen HM, Nilsen H, Lu JH, Fang EF. Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng. 2022 Jan 06; doi: 10.1038/s41551-021-00819-5. Epub 2022 Jan 06. PMID: 34992270.
Copy Download .nbib Format: NLM
Comparison of endovascular strategy versus hybrid procedure in treatment of chronic venous obstructions involving the confluence of common femoral vein.

Journal of vascular surgery. Venous and lymphatic disorders

Piao L, Barbati ME, Shekarchian S, Jacobs MJ, Razavi M, Rass K, Jalaie H, Caldwell G, Bilandzic M, Foth M.
PMID: 34478907
J Vasc Surg Venous Lymphat Disord. 2021 Aug 31; doi: 10.1016/j.jvsv.2021.08.016. Epub 2021 Aug 31.

OBJECTIVE: Treatment of extensive chronic venous obstruction (CVO) with post-thrombotic trabeculation involving the common femoral vein with extension into the femoral vein or deep femoral vein remains a challenge and the best treatment technique for such cases is not...

Cite
Piao L, Barbati ME, Shekarchian S, et al. Comparison of endovascular strategy versus hybrid procedure in treatment of chronic venous obstructions involving the confluence of common femoral vein. J Vasc Surg Venous Lymphat Disord. 2021;doi: 10.1016/j.jvsv.2021.08.016.
Piao, L., Barbati, M. E., Shekarchian, S., Jacobs, M. J., Razavi, M., Rass, K., Jalaie, H., Caldwell, G., Bilandzic, M., & Foth, M. (2021). Comparison of endovascular strategy versus hybrid procedure in treatment of chronic venous obstructions involving the confluence of common femoral vein. Journal of vascular surgery. Venous and lymphatic disorders, . https://doi.org/10.1016/j.jvsv.2021.08.016
Piao, Long, et al. "Comparison of endovascular strategy versus hybrid procedure in treatment of chronic venous obstructions involving the confluence of common femoral vein." Journal of vascular surgery. Venous and lymphatic disorders vol. (2021). doi: https://doi.org/10.1016/j.jvsv.2021.08.016
Piao L, Barbati ME, Shekarchian S, Jacobs MJ, Razavi M, Rass K, Jalaie H, Caldwell G, Bilandzic M, Foth M. Comparison of endovascular strategy versus hybrid procedure in treatment of chronic venous obstructions involving the confluence of common femoral vein. J Vasc Surg Venous Lymphat Disord. 2021 Aug 31; doi: 10.1016/j.jvsv.2021.08.016. Epub 2021 Aug 31. PMID: 34478907.
Copy Download .nbib Format: NLM
Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury.

Experimental neurology

Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, Abdelrahman AA, Cheng PN, Narayanan SP, Caldwell RW, Caldwell RB.
PMID: 34780773
Exp Neurol. 2021 Nov 12;348:113923. doi: 10.1016/j.expneurol.2021.113923. Epub 2021 Nov 12.

Arginase 1 (A1) is the enzyme that hydrolyzes the amino acid, L-arginine, to ornithine and urea. We have previously shown that A1 deletion worsens retinal ischemic injury, suggesting a protective role of A1. In this translational study, we aimed...

Cite
Fouda AY, Eldahshan W, Xu Z, et al. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2021;348:113923doi: 10.1016/j.expneurol.2021.113923.
Fouda, A. Y., Eldahshan, W., Xu, Z., Lemtalsi, T., Shosha, E., Zaidi, S. A., Abdelrahman, A. A., Cheng, P. N., Narayanan, S. P., Caldwell, R. W., & Caldwell, R. B. (2021). Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Experimental neurology, 348113923. https://doi.org/10.1016/j.expneurol.2021.113923
Fouda, Abdelrahman Y, et al. "Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury." Experimental neurology vol. 348 (2021): 113923. doi: https://doi.org/10.1016/j.expneurol.2021.113923
Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, Abdelrahman AA, Cheng PN, Narayanan SP, Caldwell RW, Caldwell RB. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2021 Nov 12;348:113923. doi: 10.1016/j.expneurol.2021.113923. Epub 2021 Nov 12. PMID: 34780773.
Copy Download .nbib Format: NLM
Showing 241 to 245 of 245 entries